Orforglipron hype at ObesityWeek 2025: what the data show

What did @summerthedietitian actually say?

She corrected herself and her audience on the pronunciation of orforglipron, an oral GLP-1 receptor agonist in late-stage development at Eli Lilly. She says she confirmed directly with "the Lily rep" that the correct pronunciation is "or-for-GLIP-ron," not "or-FOR-glip-ron" as she had apparently been saying for about a year. She also took a jab at people still mispronouncing tirzepatide, calling them out as "manjerno people." Playful delivery, but a genuine correction about a drug name that matters as it gets closer to market.

This is a short, low-stakes video, but pronunciation accuracy for emerging drug names has real-world relevance. Pharmacists, patients, and prescribers will need to communicate clearly about this medication, and confusion around drug names is a documented contributor to medication errors (Lambert et al., 2010, Drug Safety).

Does the science back this up?

There is no peer-reviewed paper on how to pronounce orforglipron, obviously. But what we can verify is whether orforglipron is a real drug, what it does, and whether a Lilly rep is a credible source for its pronunciation. On all three counts, the answer is yes.

Orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide or tirzepatide, it does not require injection and is taken orally once daily. Phase 3 clinical trials are ongoing. Data presented at ObesityWeek 2024 and published by Wharton et al. in The New England Journal of Medicine (2024) showed meaningful weight loss and glycemic improvements in adults with type 2 diabetes. Lilly's own press materials and clinical trial registrations consistently use the spelling "orforglipron," and drug nomenclature bodies like USAN (United States Adopted Names Council) set these names, including their intended pronunciation. A Lilly medical affairs representative would have access to that guidance.

What did they get wrong (or right)?

Mostly right, and credit where it is due. Self-correcting publicly after a year of mispronunciation takes some honesty. The phonetic breakdown she offers, "or-for-GLIP-ron," is consistent with how USAN-derived stems typically work. The "-glipron" stem signals the drug class, and stressing the class-identifying syllable is standard practice in pharmaceutical naming conventions.

The one thing worth flagging is the casual citation of "the Lily rep" as the authoritative source. That is not wrong, but it is worth knowing that Lilly's promotional representatives are not always the most precise medical information sources. The gold standard for pronunciation would be USAN's official monograph or Lilly's medical information line. That said, for a TikTok correction video, sourcing a company rep is reasonable, and nothing here contradicts publicly available information about the drug name.

The "manjerno" joke about tirzepatide is a light callback to the years of widespread mispronunciation of Mounjaro. Tirzepatide is correctly pronounced "tir-ZEP-a-tide," which many people did get wrong initially. That part checks out too.

What should you actually know?

Orforglipron is not approved yet. As of mid-2025, it is in Phase 3 trials, and no FDA approval has been granted. That means it is not available by prescription, compounded, or otherwise, and anyone selling it right now is selling something unregulated. If you hear about it from a telehealth platform before an FDA decision, ask hard questions.

What makes orforglipron scientifically interesting is the oral delivery mechanism. Current approved GLP-1 options either require weekly injections (semaglutide, tirzepatide) or a complex oral formulation with strict fasting requirements (oral semaglutide, Rybelsus). Orforglipron is a true small molecule, meaning it does not degrade in the gut the way peptide-based GLP-1 drugs do. Early Phase 2 data (Rosenstock et al., 2023, NEJM) showed weight reductions of up to 14.7 percent over 36 weeks, which is competitive with injectable options in early-stage comparisons, though head-to-head trials have not been completed.

Knowing how to say a drug name correctly matters more than it sounds. Verbal prescription errors, pharmacist mishearing, and patient confusion are real risks when a new drug enters widespread use. Getting the pronunciation right before it hits pharmacy shelves is actually useful prep work.